Your session is about to expire
← Back to Search
Embolization Agent
Prostate Artery Embolization for Enlarged Prostate
N/A
Waitlist Available
Led By Cliff Davis, MD
Research Sponsored by Tampa General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patient is aged 50-85 years
Patient has signed informed consent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up safety will be evaluated throughout the initial 12 months of the study by assessing adverse events and findings on physical examination.
Awards & highlights
Study Summary
This trial will test the effectiveness of a new treatment for enlarged prostate that is causing urinary problems.
Eligible Conditions
- Enlarged Prostate
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ safety will be evaluated throughout the initial 12 months of the study by assessing adverse events and findings on physical examination.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~safety will be evaluated throughout the initial 12 months of the study by assessing adverse events and findings on physical examination.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Improvement of BPH symptoms as assessed by the IPSS at 12 months post PAE.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Prostate Artery EmbolizationExperimental Treatment1 Intervention
Embospheres microspheres
Find a Location
Who is running the clinical trial?
Tampa General HospitalLead Sponsor
19 Previous Clinical Trials
3,865 Total Patients Enrolled
Cliff Davis, MDPrincipal InvestigatorTampa General Hospital
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger